Please Wait
Applying Filters...
menu
    • menu

    List of Drug Master Files (DMF) of Magaldrate Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Email Product
    US, Europe turn to advanced manufacturing, stockpiling to strengthen drug supply chains

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    Magaldrate

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4Xls download

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    26/09/2024 Priti Industries
    India
    		 PRITI INDUSTRIES 39249 MAGALDRATE IP/BP/USP 2023-12-06 Active II N/A
    26/09/2024 Tomita Pharmaceutical
    Japan
    		 TOMITA PHARMACEUTICAL CO LTD 30140 MAGALDRATE POWDER USP 2015-12-23 Inactive II N/A